Table 1 Clinical characteristics of patients (PCa) and controls (BPH) in the Training, Validation1 and Validation 2 cohorts
Training cohort | Validation cohort 1 | Validation cohort 2 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
All n = 70 | BPH n = 37 52% | PCa n = 33 48% | p | All n = 90 | BPH n = 45 50% | PCa n = 45 50% | p | All n = 110 | BPH n = 65 59% | PCa n = 45 41% | p | ||||||
Age (Years) | 67.15 ± 9 | 65.2 ± 10 | 69.1 ± 8 | .314 | Age (Years) | 68 ± 8 | 66 ± 8 | 69.8 ± 7.8 | .061 | Age (Years) | 69 ± 7.3 | 67.1 ± 7 | 70 ± 7.2 | .154 | |||
PSA (ng/ml) | 7.8 ± 5.5 | 5.6 ± 2 | 10 ± 5 | .001 | PSA (ng/ml) | 8.78 ± 6 | 8.7 ± 4.8 | 8.8 ± 5.6 | .769 | PSA (ng/ml) | 7 ± 5.8 | 7 ± 5.3 | 7.2 ± 6.7 | .874 | |||
TRUS Volume (ml) | 53.5 ± 29 | 68 ± 28 | 39 ± 12 | .001 | TRUS Volume (ml) | 51.8 ± 28 | 55 ± 23 | 48 ± 21 | .321 | TRUS Volume (ml) | 55 ± 27 | 61 | 45.5 ± 19 | .053 | |||
EG < 2 n = 14 42% | EG > 3 n = 19 45% | EG < 2 n = 12 27% | EG > 3 n = 19 73% | EG < 2 n = 28 62% | EG > 3 n = 17 38% | ||||||||||||
Age (Years) | 69.8 ± 7.7 | 67 ± 8 | .743 | Age (Years) | 68.5 ± 7.3 | 70 ± 8 | .465 | Age (Years) | 69 ± 7 | 73 ± 7 | .308 | ||||||
PSA (ng/ml) | 10 ± 6.8 | 9.6 ± 4.5 | .924 | PSA (ng/ml) | 5.8 ± 2 | 9.9 ± 6.2 | .022 | PSA (ng/ml) | 6.5 ± 2.9 | 9.06 ± 7 | .029 | ||||||
TRUS Volume (ml) | 37 ± 12 | 40 ± 11 | .487 | TRUS Volume (ml) | 48 ± 27 | 48 ± 18 | .906 | TRUS Volume (ml) | 43.5 ± 19 | 54.5 ± 19 | .664 | ||||||